Epidemiology of non-alcoholic fatty liver disease in Asia

Wong, Sui‐Weng; Chan, Wah‐Kheong

doi:10.1007/s12664-020-01018-x

Cited by 47 publications

(37 citation statements)

References 82 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…2,3 Consequently, both liver diseases are frequently observed together with an estimated 30% having hepatic steatosis among those with CHB. 4 Studies have shown that hepatic steatosis may be associated with favourable virologic status in CHB patients, with reduced hepatitis B viral load and accelerated hepatitis B surface antigen (HBsAg) seroclearance. 5,6 On the contrary, hepatic steatosis has been associated with increased fibrosis progression in CHB patients, regardless of antiviral treatment status.…”

Section: Introductionmentioning

confidence: 99%

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

Wong

Chan

Mohamed

2020

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

Hepatic steatosis is increasingly common and has been implicated in progression of liver fibrosis in chronic hepatitis B (CHB) patients. We aimed to investigate the impact of hepatic steatosis on liver fibrosis and clinical outcomes in CHB patients. Consecutive CHB patients who underwent transient elastography between 2013 and 2017 at a tertiary hospital were included in this longitudinal cohort study. Presence of hepatic steatosis was defined as controlled attenuation parameter, CAP ≥ 248 dB/m, while advanced liver fibrosis was defined as liver stiffness measurement, LSM ≥ 9.4 kPa. Cardiovascular events, liver-related complications, malignancy and mortality and a composite of these outcomes were evaluated with Kaplan-Meier analysis and Cox proportional hazards regression. Our study cohort included 614 patients with median follow-up of 45 (32-63) months. Hepatic steatosis was present in 294 patients (47.9%), and advanced liver fibrosis was present in 127 patients (21.0%).

show abstract

Section: Introductionmentioning

confidence: 99%

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

Wong

Chan

Mohamed

2020

Journal of Viral Hepatitis

Self Cite

View full text Add to dashboard Cite

show abstract

“…Metabolic dysfunction-associated fatty liver disease (MAFLD), also known as nonalcoholic fatty liver disease (NAFLD), is widely recognized as the most common cause of chronic liver disease worldwide, affecting over one-quarter of the global population. 1,2 The overall prevalence of MAFLD in Asia is estimated to be 29.6% up till now. 2 Due to great changes in lifestyles and dietary habits, MAFLD has become a great social health burden in China, with prevalence of 18.2% in 2000-2006, 20.0% in 2007-2009, and 20.9% in 2010-2013.…”

Section: Introductionmentioning

confidence: 99%

“…1,2 The overall prevalence of MAFLD in Asia is estimated to be 29.6% up till now. 2 Due to great changes in lifestyles and dietary habits, MAFLD has become a great social health burden in China, with prevalence of 18.2% in 2000-2006, 20.0% in 2007-2009, and 20.9% in 2010-2013. 3,4 A recent meta-analysis reported that the national prevalence of MAFLD in China had reached up to 29.1%.…”

Section: Introductionmentioning

confidence: 99%

FTO Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population

Zhan

Yuan

et al. 2020

CIA

View full text Add to dashboard Cite

Background: As fat and obesity play a vital role in the pathophysiology of metabolic dysfunction-associated fatty liver disease (MAFLD), this study aims to investigate the association between the fat mass and obesity-associated gene (FTO) and MAFLD. Methods: Six SNPs (rs6499640, rs1421085, rs8050136, rs3751812, rs9939609 and rs9930506) within FTO were genotyped for 741 MAFLD patients (median age, 69.98; interquartile range, 66.55-75.93) and 825 healthy people (median age, 69.94; interquartile range, 66.39-75.64). Allele and genotype frequencies, pairwise linkage disequilibrium (LD) and haplotype analysis were calculated. Results: BMI, waist circumference, systolic blood pressure, diastolic blood pressure, fasting plasma glucose, triglyceride, alanine transaminase, glutamyl transpeptidase and the prevalence of diabetes were found to be higher in the MAFLD individuals comparing to the control ones (P < 0.05). For rs1421085, the C allele frequency was remarkably higher in MAFLD after Bonferroni correction (OR [95% CI] =1.353 [1.095-1.671]; P corr =0.030), and a significantly different genotype result was observed in log-additive model (OR [95% CI] =1.369 [1.108-1.691]; P corr =0.024). For rs8050136, significantly increased A allele frequency was observed in MAFLD (OR [95% CI] =1.371 [1.109-1.695]; P corr =0.024), and A-allele carriers showed increased MAFLD risk (OR [95% CI] =1.393 [1.103-1.759]; P corr =0.030). For rs3751812, the T allele frequency was remarkably higher in MAFLD (OR [95% CI] =1.369 [1.108-1.691]; P corr =0.024), and T-allele carriers demonstrated high MAFLD risk (OR [95% CI] =1.392 [1.103-1.756]; P corr =0.030). For rs9939609, A allele frequency was also remarkably high in MAFLD (OR [95% CI] =1.369 [1.108-1.691]; P corr =0.024), and A-allele carriers were more susceptible to MAFLD (OR [95% CI] =[1.103-1.756]; P corr =0.030). A strong LD was found among rs1421085, rs8050136, rs3751812 and rs9939609 (r 2 >0.8), and individuals with C-AT A haplotype had an elevated MAFLD risk (P =0.005). Conclusion: The case-control study indicated that C variant of rs1421085, A variant of rs8050136, T variant of rs3751812 and A variant of rs9939609 are associated with elevated MAFLD risk in the older Chinese Han population.

show abstract

“…However, the overall prevalence of NAFLD in Asia is now estimated to be 29.6% and may have surpassed that in Western countries. 2 The incidence rate of NAFD has been increasing on a yearly basis, and the median age of those patients has steadily declined, making NAFD a significant public health problem. [3][4][5] NAFLD is a general term that includes diseases such as simple nonalcoholic fatty liver disease, nonalcoholic fatty liver hepatitis (NASH), liver fibrosis, liver cirrhosis, and even late-stage hepatocellular carcinoma.…”

Section: Introductionmentioning

confidence: 99%

Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy

Zhang¹,

Deng²,

Xiang³

et al. 2020

DDDT

View full text Add to dashboard Cite

Background: Previous studies have shown that curcumin derivatives can improve the fatty degeneration of liver tissue that occurs in nonalcoholic fatty liver disease (NAFLD). However, the specific mechanism for that improvement remains unclear. We examined whether the curcumin derivative galangin could reduce the fatty degeneration of liver tissue in mice with NAFLD by inducing autophagy, from the perspective of both prevention and treatment. Methods: C57BL/6J mice were randomly assigned to a prevention group (given galangin and a HFD simultaneously) or a treatment group (given galangin after being fed an HFD). The prevention group was treated with galangin (100 mg/kg/d) or an equal volume of normal saline (NS) while being fed an HFD. Some mice were treated with an autophagy inhibitor (3-methyladenine, 3-MA; 30 mg/kg/biwk, i.p.) while being fed an HFD and galangin. HepG2 cells were cultured in DMEM medium containing both free fatty acids and galangin. Results: Galangin was found to reduce the fatty degeneration of liver tissue induced by eating an HFD at both the prevention and treatment levels, and that effect might be related to an enhancement of hepatocyte autophagy. Inhibition of autophagy by 3-MA blocked the protective effect of galangin on hepatic steatosis. At the cellular level, galangin reduced lipid accumulation and enhanced the level of hepatocyte autophagy. Conclusion: In vitro and in vivo studies showed that galangin cannot only improve preexisting hepatic steatosis but also prevent the development of stenosis by promoting hepatocyte autophagy.

show abstract

Epidemiology of non-alcoholic fatty liver disease in Asia

Cited by 47 publications

References 82 publications

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

Fatty liver is associated with advanced fibrosis but does not predict adverse outcomes in patients with chronic hepatitis B

<p><em>FTO</em> Polymorphisms are Associated with Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Susceptibility in the Older Chinese Han Population</p>

<p>Galangin Improved Non-Alcoholic Fatty Liver Disease in Mice by Promoting Autophagy</p>

Contact Info

Product

Resources

About